EP4200288A4 - Compounds and methods for treating autoimmune disorders by targeting hla-dq2 - Google Patents
Compounds and methods for treating autoimmune disorders by targeting hla-dq2Info
- Publication number
- EP4200288A4 EP4200288A4 EP21859188.1A EP21859188A EP4200288A4 EP 4200288 A4 EP4200288 A4 EP 4200288A4 EP 21859188 A EP21859188 A EP 21859188A EP 4200288 A4 EP4200288 A4 EP 4200288A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- methods
- autoimmune disorders
- treating autoimmune
- targeting hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063068631P | 2020-08-21 | 2020-08-21 | |
PCT/US2021/046860 WO2022040508A1 (en) | 2020-08-21 | 2021-08-20 | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4200288A1 EP4200288A1 (en) | 2023-06-28 |
EP4200288A4 true EP4200288A4 (en) | 2024-10-30 |
Family
ID=80270497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21859188.1A Pending EP4200288A4 (en) | 2020-08-21 | 2021-08-20 | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11939300B2 (en) |
EP (1) | EP4200288A4 (en) |
WO (1) | WO2022040508A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068170A2 (en) * | 2002-02-14 | 2003-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
-
2021
- 2021-08-20 US US17/407,565 patent/US11939300B2/en active Active
- 2021-08-20 WO PCT/US2021/046860 patent/WO2022040508A1/en unknown
- 2021-08-20 EP EP21859188.1A patent/EP4200288A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068170A2 (en) * | 2002-02-14 | 2003-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
Non-Patent Citations (1)
Title |
---|
See also references of WO2022040508A1 * |
Also Published As
Publication number | Publication date |
---|---|
US11939300B2 (en) | 2024-03-26 |
WO2022040508A1 (en) | 2022-02-24 |
US20220055994A1 (en) | 2022-02-24 |
EP4200288A1 (en) | 2023-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL304429A (en) | Methods and compositions for treatment of epileptic disorders | |
IL289970A (en) | Compositions and methods for treating autoimmune disorders | |
IL289173A (en) | Compositions and methods for treating cns disorders | |
SG11202009371WA (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
IL289172A (en) | Compositions and methods for treating cns disorders | |
IL291687A (en) | Methods for treating myelofibrosis and related conditions | |
IL270114B1 (en) | Methods and compositions for treating neurological disorders | |
IL288655A (en) | Compositions and methods for treating central nervous system disorders | |
EP3826650A4 (en) | Methods of treating neurological disorders | |
IL294594A (en) | Methods for treating pemphigus disorders | |
IL281736A (en) | Methods of treating myeloproliferative disorders | |
IL275985A (en) | Compositions and methods for treating retinal disorders | |
EP3826649A4 (en) | Methods of treating neurological disorders | |
SG11202011151VA (en) | Compositions and methods for reducing spliceopathy and treating rna dominance disorders | |
EP4188368A4 (en) | Compositions and methods for treating diseases and disorders | |
IL313097A (en) | Methods of treating cns disorders | |
IL292678A (en) | Methods of treating depressive disorders | |
GB201914034D0 (en) | Treatment of neurological disorders | |
IL286571A (en) | Compositions and methods for treating neurodegenerative disorders | |
IL292186A (en) | Compositions and methods for treating blood disorders | |
EP4200288A4 (en) | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 | |
IL313539A (en) | Methods for treating neurological disorders | |
IL311852A (en) | Compositions and methods for treating neurological disorders | |
IL289018A (en) | Methods for treating neurodegenerative disorders | |
IL291639A (en) | Method for treating mood disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07D0307330000 Ipc: C07D0237280000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240930 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/02 20060101ALI20240925BHEP Ipc: A61K 31/502 20060101ALI20240925BHEP Ipc: C07D 405/06 20060101ALI20240925BHEP Ipc: C07D 403/04 20060101ALI20240925BHEP Ipc: C07D 401/12 20060101ALI20240925BHEP Ipc: C07D 405/04 20060101ALI20240925BHEP Ipc: C07D 237/28 20060101AFI20240925BHEP |